Biohaven LTD 8-K filings

Biohaven Ltd. announced second quarter 2026 financial results and significant clinical advancements, including pivotal trial initiations for BHV-1300 and BHV-1400, and positive data for opakalim.

Biohaven Ltd. announced the appointment of John Yetimoglu to its Board of Directors, effective August 6, 2026, strengthening its Nominating and Governance Committee.

Biohaven Ltd. announces scientific leadership role transitions, promoting David Pirman, Ph.D., to EVP and Head of Discovery, and Bruce Car, Ph.D., to Chief Innovation Officer.

Biohaven presented positive clinical data for its epilepsy, immunology, and oncology programs, confirming pivotal trial initiations for 2026.

Biohaven Ltd. has amended its Equity Distribution Agreement with J.P. Morgan Securities LLC, allowing for potential sales of up to $350 million in common shares.

Biohaven Ltd. announced its first quarter 2026 financial results, highlighting progress in its epilepsy, obesity, and rare disease programs, with several pivotal trials set to initiate.

Biohaven Ltd. shareholders approved director elections, auditor ratification, and executive compensation at the 2026 Annual Meeting.

Biohaven Ltd. reported Q4 and full-year 2025 financial results, highlighting significant pipeline advancements in immunology, epilepsy, and obesity, alongside strategic cost optimization and recent capital raises.

Biohaven Ltd. presented a robust pipeline update, highlighting positive clinical data across its degrader, ion channel, myostatin activin, and oncology programs, alongside a significant capital raise.

Biohaven Ltd. announced it will issue and sell 12.5 million common shares to Janus Henderson Investors for $125 million in gross proceeds.

Biohaven Ltd. successfully completed a registered public offering, issuing 26,833,334 common shares and raising approximately $200 million in gross proceeds.

Biohaven Ltd. reported third-quarter 2025 financial results, detailing strategic cost optimization and a sharpened focus on three late-stage clinical programs.

The FDA has determined an advisory committee meeting is no longer needed for Biohaven's troriluzole New Drug Application for Spinocerebellar Ataxia, maintaining the Q4 2025 decision timeline.

Biohaven Ltd. filed a prospectus supplement for the resale of shares, revealing an amendment to its Knopp Biosciences agreement that substantially reduces future milestone payments.

Biohaven Ltd. reported its second quarter 2025 financial results, highlighting significant progress across its clinical pipeline, including positive data for its degrader and ADC platforms, and anticipation of a regulatory decision for VYGLXIA in SCA.

Biohaven Ltd. highlights significant advancements in its diverse clinical pipeline, including priority review for troriluzole in SCA, multiple pivotal trial initiations for its degrader platform, and promising early data for its next-generation ADCs, positioning the company for multiple value-inflection points in 2025-2026.

The FDA has extended the PDUFA date for Biohaven's troriluzole NDA for spinocerebellar ataxia by three months, and plans to hold an advisory committee meeting to discuss the application.

Biohaven announces Q1 2025 financial results, a $600 million non-dilutive capital agreement, and progress in its clinical programs.

Biohaven Ltd. held its 2025 annual meeting of shareholders on May 5, 2025, and all proposals, including the election of directors and ratification of Ernst & Young LLP as independent auditors, were approved.

Biohaven has secured a non-dilutive investment of up to $600 million from Oberland Capital in exchange for capped milestone and royalty payments on future troriluzole product net sales.

Biohaven announces FDA acceptance of troriluzole NDA with Priority Review, positive degrader data, and provides a review of recent accomplishments and financial results for Q4 and full year 2024.

Biohaven showcased its diverse pipeline at the J.P. Morgan Healthcare Conference, emphasizing its novel degrader platform and advancements in clinical trials across multiple therapeutic areas.

Biohaven reports positive topline results for troriluzole in spinocerebellar ataxia, along with third quarter 2024 financial results and pipeline updates.

Biohaven Ltd. successfully completed a public offering of 6,052,631 common shares, generating gross proceeds of approximately $287.5 million.

Biohaven's troriluzole demonstrated significant efficacy in slowing the progression of Spinocerebellar Ataxia (SCA) in a pivotal study, paving the way for a potential new treatment.

Biohaven Ltd. has filed a prospectus supplement for the resale of 1,872,874 common shares by a selling shareholder, originally issued as part of a prior business transaction.

Biohaven Ltd. has amended its equity distribution agreement to potentially sell an additional $300 million of its common shares through an at-the-market offering.

Biohaven announced its second quarter 2024 financial results, highlighting advancements in its drug pipeline, including its MoDE platform and multiple clinical trials.

Biohaven Ltd. has filed a prospectus supplement for the resale of 211,418 common shares by selling shareholders, originally issued as part of a merger agreement.

Biohaven announced its first quarter 2024 financial results, highlighted by a public offering raising $247.8 million and advancements in its clinical pipeline, including its novel MoDE technology.